 |
 |
 |
 |
 |
 |
 |
|
|
|
|||||||||
|
|||||||||||
Research Articles |
Zomepirac sodium is a nonsteroidal antiinflammatory drug with potent analgesic properties. Since its introduction in October 1980, this prostaglandin inhibitor has been fairly well tolerated, and little toxicity has been associated with its use. In fact, it was not until April 1981 that the first serious reaction of anaphylaxis was described. Since then six additional cases have been reported to the literature. The manufacturer voluntarily withdrew the agent in March 1983 from the market pending further investigation of these reactions. We describe the case of an additional anaphylactic reaction to zomepirac and review the literature.
This article has been cited by other articles:
|
|
 |
|
  Q. Chen, G. A. Doss, E. C. Tung, W. Liu, Y. S. Tang, M. P. Braun, V. Didolkar, J. R. Strauss, R. W. Wang, R. A. Stearns, et al. EVIDENCE FOR THE BIOACTIVATION OF ZOMEPIRAC AND TOLMETIN BY AN OXIDATIVE PATHWAY: IDENTIFICATION OF GLUTATHIONE ADDUCTS IN VITRO IN HUMAN LIVER MICROSOMES AND IN VIVO IN RATS Drug Metab. Dispos., January 1, 2006; 34(1): 145 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Grillo and F. Hua IDENTIFICATION OF ZOMEPIRAC-S-ACYL-GLUTATHIONE IN VITRO IN INCUBATIONS WITH RAT HEPATOCYTES AND IN VIVO IN RAT BILE Drug Metab. Dispos., November 1, 2003; 31(11): 1429 - 1436. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
 |
 |
 |
 |
